🧬 MariTide

What Is MariTide?

MariTide (maridebart cafraglutide, formerly AMG 133) is an investigational antibody–peptide conjugate developed by Amgen for the treatment of obesity and related conditions . It is designed to be administered as a monthly or potentially less frequent subcutaneous injection, leveraging its long half‑life (approximately 21 days) to improve patient convenience and adherence .

MariTide emerged from Amgen’s deep expertise in human genetics and preclinical biology. As Jay Bradner, head of R&D at Amgen, stated: “MariTide exemplifies how Amgen converts deep genetic insights into bold therapeutic strategies.”

Mechanism of Action

MariTide is a bispecific molecule with a unique dual mechanism :

This GIPR antagonist strategy is a deliberate departure from other dual‑targeting drugs like tirzepatide, which acts as a GIPR agonist. Amgen’s approach was informed by preclinical findings that GIPR knockout protected mice from diet‑induced obesity, and by human genetic data linking GIPR variants to lower BMI .

Human Genetics Rationale

The scientific foundation for MariTide is rooted in human genetics. Researchers at Amgen’s deCODE genetics subsidiary analyzed genetic data from hundreds of thousands of individuals and identified variants in the GIPR gene associated with lower body mass index . These variants disrupted GIPR function, suggesting that reduced GIP signaling may be protective against obesity .

• Preclinical validation: Mice with global or CNS‑specific GIPR knockout were protected from high‑fat diet‑induced obesity .
• Synergistic effect: Combining GIPR antagonism with GLP‑1 agonism in animal models produced greater weight loss than either molecule alone .
• Clinical translation: Phase 1 data confirmed that MariTide’s dual mechanism was well‑tolerated and induced dose‑dependent weight loss in humans .

Phase 2 Data (Published in NEJM, 2025)

The Phase 2 trial (NCT05669599) was a double‑blind, randomized, placebo‑controlled, dose‑ranging study that enrolled 592 participants into two cohorts .

• Cohort A: 465 participants with obesity without Type 2 diabetes (mean BMI 37.9).
• Cohort B: 127 participants with obesity and Type 2 diabetes (mean BMI 36.5).
• Dosing: Monthly subcutaneous injections of 140, 280, or 420 mg, with some groups using dose escalation (starting at 70 mg) over 4 or 12 weeks .
• Primary endpoint: Percent change in body weight from baseline to week 52 .

Efficacy Results

📊 Key Findings (52 Weeks)

• Cohort A (obesity, no diabetes): Mean weight loss ranged from 12.3% to 16.2% per treatment‑policy estimand, and 16.3% to 19.9% per efficacy estimand .
• Cohort B (obesity + T2D): Mean weight loss ranged from 8.4% to 12.3% per treatment‑policy estimand, and 12.1% to 17.0% per efficacy estimand . HbA1c reductions of up to 1.6 percentage points were observed .
• No plateau: Weight loss had not plateaued by week 52, suggesting the potential for further weight reduction with longer treatment .
• Cardiometabolic improvements: Significant reductions were observed in waist circumference, blood pressure, high‑sensitivity C‑reactive protein (hs‑CRP), and select lipid parameters .

An unexpected finding was that weight loss in patients with T2D was nearly as robust as in those without diabetes—a notable deviation from other incretin‑based therapies, where diabetes status typically attenuates weight loss .

Safety & Tolerability

MariTide’s safety profile was consistent with the GLP‑1 class, with gastrointestinal events being the most common .

⚠️ Common Adverse Events

• Nausea, vomiting, constipation, diarrhea: The most frequently reported AEs, predominantly mild to moderate in severity .
• MINVR reporting: The study used a rigorous daily patient‑reported outcome tool (Modified Index of Nausea/Vomiting/Retching) to capture GI symptoms, which likely contributed to higher reporting rates than in other trials .
• Dose escalation improved tolerability: Starting at a lower dose (70 mg) and titrating to 420 mg over 4 or 12 weeks substantially reduced GI side effects . In dose‑escalation arms, discontinuation due to GI AEs was < 8%, compared to 12–27% in fixed‑dose arms .
• Nausea and vomiting were episodic: Typically resolving within a median of 6 days (nausea) and 1–2 days (vomiting) .

📋 Serious Considerations

• No unexpected safety signals were identified in the Phase 2 trial .
• Discontinuation rates: In the obesity cohort, discontinuation due to any AE in dose‑escalation arms was ~11%, and less than 8% due to GI events .
• Long‑term safety: Phase 3 trials will provide larger‑scale safety data .

Phase 3 MARITIME Program

Amgen has initiated a large Phase 3 clinical program called MARITIME, which the company describes as one of the largest in its 45‑year history .

• MARITIME‑1: Study for people living with overweight or obesity without Type 2 diabetes .
• MARITIME‑2: Study for people living with Type 2 diabetes and overweight or obesity .
• Additional studies: Exploring MariTide in cardiovascular disease, heart failure, kidney disease, and obstructive sleep apnea .
• Titration strategy: Phase 3 will use an optimized 8‑week dose escalation (21 mg → 35 mg → 70 mg) to improve tolerability .
• Duration: 72‑week chronic weight management studies .

MariTide represents a bold, genetically‑informed approach to obesity treatment. By combining GLP‑1 receptor agonism with GIP receptor antagonism—a strategy distinct from other dual‑targeting drugs—it has the potential to offer robust weight loss with once‑monthly dosing. The Phase 2 data published in NEJM are encouraging, demonstrating up to ~20% weight loss with ongoing efficacy at 52 weeks. However, gastrointestinal tolerability remains a key challenge, and Phase 3 trials will be essential to confirm MariTide’s safety, efficacy, and real‑world value. For now, MariTide is one of the most closely watched investigational therapies in the obesity space.

❓ FAQs About MariTide

✧ Written in service of evidence‑based medicine and scientific curiosity ✧